In this article, we will look at the 11 Best Performing Long Term Stocks According to Analysts.
On September 19, Alli McCartney, Managing Director at UBS Private Wealth Management, and Philip Straehl, CIO Americas at Morningstar Wealth, joined CNBC to the rate cuts, market valuations and more.
Alli McCartney of UBS noted that the market’s behavior after the recent Fed rate cut was unusual. On the day of the cut, major indices closed lower except for the Russell 2000. The next day, all major indices hit new highs. She noted that this reflected mixed market reactions, with institutional investors waiting to see how falling employment and rate cuts would balance out. It was a cautious, interpretive phase following the Fed’s announcement.
On the other hand, Philip Straehl from Morningstar highlighted his bullish view on small-cap stocks, especially in the healthcare sector. He explained that small caps often depend on short-term borrowing and are more sensitive to Fed rate changes. Since expectations of rate cuts have increased, small caps have gained support as a result. He also noted that the small-cap value stocks still trade below their intrinsic value by 15% to 20%, so an easing cycle by the Fed could be a catalyst for their growth.
While talking about valuations, Alli McCartney noted that although the valuations are at nose-bleed levels, she pointed out that similar valuations in the past have led to gains when earnings and rate cuts aligned. She emphasized it is risky but sensible now to invest and not avoid the market, due to tailwinds including AI innovation, new stimulus, and a more aligned Fed policy. She advised investors to buy the dips when the market presents an opportunity.
With that, let’s take a look at the 11 best performing long term stocks according to analysts.
Our Methodology
To curate the list of 11 best performing long term stocks according to analysts, we used the Finviz Stock Screener, Seeking Alpha, CNN, and Insider Monkey’s Q2 2025 database as our sources. Using the screener we aggregated a list of long term stocks (5-year revenue growth rate of more than 10%) that have gained more than 30% year-to-date with analysts expecting more than 25% upside. Next, we cross-checked the revenue growth from Seeking Alpha and analyst upside from CNN. Lastly, we ranked the stocks in ascending order of the upside potential. We have also mentioned the hedge fund sentiment around each stock. Please note that the data was recorded on September 20, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
11 Best Performing Long Term Stocks According to Analysts
11. BridgeBio Pharma, Inc. (NASDAQ:BBIO)
5-year Revenue Growth Rate: 42.20%
Year-To-Date Performance: 85.71%
Number of Hedge Fund Holders: 58
Analysts Upside Potential: 26.03%
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the Best Performing Long Term Stocks According to Analysts. On September 15, H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on BridgeBio Pharma, Inc. (NASDAQ:BBIO) with a price target of $70.
The analyst noted that his positive sentiment of the company is based on the company’s lead drug candidate Encaleret, which targets autosomal dominant hypocalcemia type 1 (ADH1). ADH1 is a rare condition with high unmet medical needs and often goes undiagnosed. He highlighted that Encaleret works differently from conventional treatments and acts as a negative allosteric modulator of the calcium-sensing receptor. This mechanism directly addresses the root cause of ADH1, which current therapies do not fully manage.
Moreover, the drug has shown strong results in a Phase 2 trial. Over 42 months, it helped normalize patients’ blood calcium, parathyroid hormone, and urine calcium levels. Importantly, Encaleret demonstrated a durable effect and a good safety profile over this long-term study.
In the United States alone there are around 12,000 patients affected by ADH1, presenting a sizable market opportunity for BridgeBio Pharma, Inc. (NASDAQ:BBIO).
BridgeBio Pharma, Inc. (NASDAQ:BBIO) discovers and develops medicines for genetic diseases. Its drug pipeline includes treatments for amyloidosis, achondroplasia, hypocalcemia, and muscular dystrophy.
10. Ascendis Pharma A/S (NASDAQ:ASND)
5-year Revenue Growth Rate: 125.53%
Year-To-Date Performance: 43.25%
Number of Hedge Fund Holders: 45
Analysts Upside Potential: 26.22%
Ascendis Pharma A/S (NASDAQ:ASND) is one of the Best Performing Long Term Stocks According to Analysts. On September 15, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ascendis Pharma A/S (NASDAQ:ASND) with a price target of $230.
The firm named the company as one of its top picks for 2025. This comes after the company’s Yorvipath global launch in hypoparathyroidism showed strong initial results with further acceleration as payor coverage expands.
The analyst noted that the company’s strong execution is reflected in its impressive 54.5% revenue growth over the last twelve months, maintaining a robust gross margin of 84.88%. Moreover, Ahmad also believes that Yorvipath is well-positioned to capture market share as the only marketed product in its category, with competing pipeline products reportedly several years behind in development. The bank currently models $3.15 billion in peak sales for Yorvipath in HPT, which it calculates represents $147 per share in value.
Ascendis Pharma A/S (NASDAQ:ASND) is a Denmark-based pharmaceutical company that develops treatments for growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes.
9. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
5-year Revenue Growth Rate: 20.98%
Year-To-Date Performance: 30.87%
Number of Hedge Fund Holders: 33
Analysts Upside Potential: 26.95%
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the Best Performing Long Term Stocks According to Analysts. On September 12, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced interim results from its LOTUS study on DAYBUE for Rett syndrome patients. The study included 227 patients aged 1 to 60 years across the United States treated with DAYBUE under routine care for up to 12 months.
The results reported behavioral improvements in 71% to 90% of patients, assessed by a questionnaire developed by the company. The most notable improvements were seen in nonverbal communication, alertness, and social interaction. Moreover, quality of life also showed modest gains in the subset assessed at 12 months.
Management noted that the median dose reached about 80% of the target FDA-approved dose after 10 weeks. Limitations of this real-world study include no placebo arm, reliance on caregiver reports, and incomplete data at later timepoints. The results support that long-term DAYBUE treatment can improve Rett syndrome symptoms and provide new insights on managing GI side effects in clinical practice.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company focused on developing and marketing innovative therapies for central nervous system disorders and rare diseases.
8. Sezzle Inc. (NASDAQ:SEZL)
5-year Revenue Growth Rate: 63.03%
Year-To-Date Performance: 101.47%
Number of Hedge Fund Holders: 30
Analysts Upside Potential: 33.73%
Sezzle Inc. (NASDAQ:SEZL) is one of the Best Performing Long Term Stocks According to Analysts. Wall Street has a mixed opinion on Sezzle Inc. (NASDAQ:SEZL) even after the company topped revenue and EPS estimates during its fiscal second quarter of 2025.
The company posted a revenue of $98.7 million, up 76.35% year-over-year and ahead of consensus by $3.77 million. The EPS of $0.69 also topped estimates by $0.11. Management noted that they achieved strong financial growth with its Gross Merchandise Volume (GMV) reaching $927 million, up 74% year-over-year. Moreover, the company’s user base grew to 748,000 Monthly On-Demand & Subscribers.
However, despite this performance Wall Street has a mixed opinion about Sezzle Inc. (NASDAQ:SEZL). On August 11, a few days after the earnings release Hal Goetsch from B. Riley Securities reiterated a Buy rating on the stock and raised the price target from $101 to $111. However, more recently, on September 11, Hoang Nguyen from TD Cowen initiated the stock with a Hold rating and a $82 price target.
Sezzle Inc. (NASDAQ:SEZL) is a fintech company that offers a digital payment platform allowing consumers to buy products instantly and pay for them in interest-free installments over time.
7. VNET Group, Inc. (NASDAQ:VNET)
5-year Revenue Growth Rate: 16.24%
Year-To-Date Performance: 90.32%
Number of Hedge Fund Holders: 27
Analysts Upside Potential: 33.88%
VNET Group, Inc. (NASDAQ:VNET) is one of the Best Performing Long Term Stocks According to Analysts. On September 11, VNET Group, Inc. (NASDAQ:VNET) announced securing a 40MW wholesale order from a major internet company for its new Gu’an IDC Campus near Beijing.
Management noted that this order will be delivered in phases, supporting the customer’s core business with premium data center services. The company will provide customized infrastructure to help the customer deploy domestic chips, which are key to China’s technological growth. Moreover, it is also implementing advanced liquid cooling technology in this project, which improves heat management, reduces energy use, and boosts power efficiency beyond regional averages.
The Gu’an IDC Campus is strategically located 51.4 kilometers south of Beijing in Hebei Province. This location allows VNET Group, Inc. (NASDAQ:VNET) to serve the overflowing demand for computing power from Beijing’s internet firms.
VNET Group, Inc. (NASDAQ:VNET) is a leading carrier-neutral and cloud-neutral internet data center service provider in China.
6. Ocular Therapeutix, Inc. (NASDAQ:OCUL)
5-year Revenue Growth Rate: 50.81%
Year-To-Date Performance: 38.44%
Number of Hedge Fund Holders: 27
Analysts Upside Potential: 40.50%
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is one of the Best Performing Long Term Stocks According to Analysts. On September 15, Daniil Gataulin from Chardan Capital initiated Ocular Therapeutix, Inc. (NASDAQ:OCUL) with a Buy rating and a $21 price target.
The analyst highlighted the company’s Axpaxli program, which is the company’s lead program and is being gradually launched over several months. Axpaxli aims to reduce the treatment burden for patients who need frequent anti-VEGF injections. These injections are commonly used for wet age-related macular degeneration and non-proliferative diabetic retinopathy. The analyst believes Axpaxli has significant potential to improve patient outcomes by lowering how often treatments are required. Gataulin suggests that this could make it a valuable option in the eye care market and the gradual release strategy allows Ocular Therapeutix, Inc. (NASDAQ:OCUL) to manage supply and uptake effectively.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on eye diseases. It develops sustained-release drug treatments using its ELUTYX hydrogel technology.
5. HEICO Corporation (NYSE:HEI.A)
5-year Revenue Growth Rate: 17.66%
Year-To-Date Performance: 34.01%
Number of Hedge Fund Holders: 69
Analysts Upside Potential: 45.71%
HEICO Corporation (NYSE:HEI.A) is one of the Best Performing Long Term Stocks According to Analysts. HEICO Corporation (NYSE:HEI.A) topped revenue and EPS estimates in FQ3 2025 with revenue of $1.15 billion ahead by $32.45 million and EPS of $1.26 ahead of consensus by $0.12.
Since the announcement, Wall Street has been bullish on the stock with several analysts reiterating their Buy ratings. For instance, on September 3, William Blair analyst Louie DiPalma reiterated a Buy rating on HEICO Corporation (NYSE:HEI.A) without disclosing any price targets. DiPalma noted the company’s solid Q3 2025 performance as one of the factors behind the bullish sentiment. The analyst noted that the Flight Support Group (FSG) achieved 13% organic growth, which is slightly slower than the previous quarter but still strong. This is notable because the company has less exposure to the engine aftermarket than its competitors yet continues to deliver high double-digit growth.
More recently, on September 5, Ronald Epstein from Bank of America Securities, reiterated a Buy rating on the stock, while raising the price target from $355 to $400.
HEICO Corporation (NYSE:HEI.A) manufactures jet engines and aircraft component replacement parts.
4. CleanSpark, Inc. (NASDAQ:CLSK)
5-year Revenue Growth Rate: 127.38%
Year-To-Date Performance: 44.13%
Number of Hedge Fund Holders: 19
Analysts Upside Potential: 47.76%
CleanSpark, Inc. (NASDAQ:CLSK) is one of the Best Performing Long Term Stocks According to Analysts. Wall Street is bullish on CleanSpark, Inc. (NASDAQ:CLSK) since the company released its fiscal third quarter results for 2025. The stock has gained more than 27% since the announcement on August 7, 2025.
CleanSpark, Inc. (NASDAQ:CLSK) delivered $198.64 million in revenue, up 90.81% year-over-year but fell short of the consensus by $1.7 million. However, the EPS of $0.78 exceeded the consensus by $0.28. Management noted achieving an operational hashrate milestone of 50 exaha shes per second (EH/s) in June 2025, making it the first public Bitcoin miner to reach this scale using exclusively American infrastructure.
Moreover, the company holds 12,703 bitcoins in its treasury, valued at over $1 billion, and has contracted more than 1 gigawatt of power capacity to sustain mining operations efficiently.
Following the update several analysts have expressed bullish sentiment on the stock. Earlier on August 8, John Todaro from Needham reiterated a Buy rating on CleanSpark, Inc. (NASDAQ:CLSK) with a price target of $21. More recently, James Mcllree from Chardan Capital also reiterated a Buy rating on the stock with a price target of $20.
CleanSpark, Inc. (NASDAQ:CLSK) is a vertically integrated Bitcoin mining company that owns and operates data centers across multiple US states, including Georgia, Mississippi, Tennessee, and Wyoming.
3. Liquidia Corporation (NASDAQ:LQDA)
5-year Revenue Growth Rate: 11.87%
Year-To-Date Performance: 96.53%
Number of Hedge Fund Holders: 43
Analysts Upside Potential: 51.39%
Liquidia Corporation (NASDAQ:LQDA) is one of the Best Performing Long Term Stocks According to Analysts. On September 3, Liquidia Corporation (NASDAQ:LQDA) presented a strategic overview at Well Fargo’s Annual Healthcare Conference 2025.
The management highlighted a strong early response to Eutrebia, its new treatment for pulmonary conditions. They noted that within eleven weeks of launch, the treatment had over 900 prescriptions and 550 patient starts. The company aims to capture a significant part of the $2 billion oral treprostinil market.
Moreover, management also noted that Liquidia Corporation (NASDAQ:LQDA) has contracts with three national players and has achieved a 75% fill rate despite initial challenges. In addition, positive ASCENT trial data supports the effectiveness of higher doses of treprostinil, which is key to Eutrebia. The company expects to reach profitability within three to four quarters, backed by a strong cash balance of over $170 million as of Q2.
Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company focused on rare cardiopulmonary diseases such as pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
2. Avidity Biosciences, Inc. (NASDAQ:RNA)
5-year Revenue Growth Rate: 16.53%
Year-To-Date Performance: 31.69%
Number of Hedge Fund Holders: 26
Analysts Upside Potential: 58.30%
Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the Best Performing Long Term Stocks According to Analysts. On September 10, Avidity Biosciences, Inc. (NASDAQ:RNA) announced positive one-year data for its, del-zota, in the EXPLORE44 and EXPLORE44-OLE trials for Duchenne muscular dystrophy patients amenable to exon 44 skipping.
Management noted that the data show a reversal of disease progression and significant functional improvements compared to baseline and natural history. Del-zota works by delivering phosphorodiamidate morpholino oligomers to muscle and heart tissue to skip exon 44 in the dystrophin gene. This enables production of near-full-length dystrophin protein, crucial for muscle protection.
The result shows that the trial participants showed about a 25% increase in dystrophin and up to 58% restored total dystrophin levels. Moreover, Creatine kinase (CK), a marker of muscle damage, dropped by over 80% and was sustained near normal. Avidity Biosciences, Inc. (NASDAQ:RNA) plans to file a Biologics License Application (BLA) with the FDA by the end of 2025 for accelerated approval, marking a major step toward a new treatment option for this severe genetic disease.
Avidity Biosciences, Inc. (NASDAQ:RNA) is a biotech company focused on creating a new class of RNA therapies called Antibody Oligonucleotide Conjugates.
1. Corcept Therapeutics Incorporated (NASDAQ:CORT)
5-year Revenue Growth Rate: 15.31%
Year-To-Date Performance: 61.14%
Number of Hedge Fund Holders: 35
Analysts Upside Potential: 70.77%
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the Best Performing Long Term Stocks According to Analysts. On September 10, Corcept Therapeutics Incorporated (NASDAQ:CORT) announced that the FDA has accepted its new drug application for Relacorilant to treat platinum-resistant ovarian cancer.
Management noted that the FDA has set a decision date of July 11, 2026, under the Prescription Drug User Fee Act. The application acceptance is based on the positive results from the Phase 3 ROSELLA trial and earlier Phase 2 studies.
In these trials, Relacorilant was combined with the chemotherapy drug nab-paclitaxel. The results showed that patients receiving this combination showed better progression-free survival and overall survival than those on nab-paclitaxel alone. Notably, Relacorilant did not add safety risks, while the rates and severity of side effects were similar between the combination and monotherapy groups.
Corcept Therapeutics Incorporated (NASDAQ:CORT) is a pharmaceutical company that discovers, develops, and commercializes medications targeting severe diseases by modulating cortisol, a hormone linked to various disorders.
While we acknowledge the potential of CORT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CORT and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
